Dabomb Protein (6578) - Net Assets
Based on the latest financial reports, Dabomb Protein (6578) has net assets worth NT$989.28 Million TWD (≈ $31.17 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.10 Billion ≈ $34.52 Million USD) and total liabilities (NT$106.48 Million ≈ $3.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Dabomb Protein to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$989.28 Million |
| % of Total Assets | 90.28% |
| Annual Growth Rate | 5.26% |
| 5-Year Change | 46.72% |
| 10-Year Change | 59.62% |
| Growth Volatility | 11.14 |
Dabomb Protein - Net Assets Trend (2015–2025)
This chart illustrates how Dabomb Protein's net assets have evolved over time, based on quarterly financial data. See how many days can Dabomb Protein fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Dabomb Protein (2015–2025)
The table below shows the annual net assets of Dabomb Protein from 2015 to 2025. For live valuation and market cap data, see 6578 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$989.28 Million ≈ $31.17 Million |
-9.18% |
| 2024-12-31 | NT$1.09 Billion ≈ $34.32 Million |
+13.70% |
| 2023-12-31 | NT$958.06 Million ≈ $30.18 Million |
+31.75% |
| 2022-12-31 | NT$727.20 Million ≈ $22.91 Million |
+7.85% |
| 2021-12-31 | NT$674.24 Million ≈ $21.24 Million |
-3.75% |
| 2020-12-31 | NT$700.51 Million ≈ $22.07 Million |
+0.30% |
| 2019-12-31 | NT$698.39 Million ≈ $22.00 Million |
-1.71% |
| 2018-12-31 | NT$710.52 Million ≈ $22.39 Million |
+14.09% |
| 2017-12-31 | NT$622.77 Million ≈ $19.62 Million |
+0.48% |
| 2016-12-31 | NT$619.77 Million ≈ $19.53 Million |
+4.58% |
| 2015-12-31 | NT$592.64 Million ≈ $18.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Dabomb Protein's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 145.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$1.06 Billion | 106.89% |
| Total Equity | NT$989.28 Million | 100.00% |
Dabomb Protein Competitors by Market Cap
The table below lists competitors of Dabomb Protein ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Harn Engineering Solutions Public Company Limited
BK:HARN
|
$37.53 Million |
|
Apex Equity Holdings Bhd
KLSE:5088
|
$37.53 Million |
|
Estrella Resources Ltd
AU:ESR
|
$37.54 Million |
|
P&K Skin Research Center Co. Ltd
KQ:347740
|
$37.54 Million |
|
Team Young Advanced Technology Co Ltd
TWO:5345
|
$37.51 Million |
|
Apollo Sindoori Hotels Limited
NSE:APOLSINHOT
|
$37.48 Million |
|
Compumedics Ltd
AU:CMP
|
$37.46 Million |
|
The Beachbody Company, Inc.
NASDAQ:BODI
|
$37.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dabomb Protein's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,089,312,000 to 989,276,000, a change of -100,036,000 (-9.2%).
- Net loss of 69,338,000 reduced equity.
- Dividend payments of 12,230,000 reduced retained earnings.
- Other factors decreased equity by 18,468,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-69.34 Million | -7.01% |
| Dividends Paid | NT$12.23 Million | -1.24% |
| Other Changes | NT$-18.47 Million | -1.87% |
| Total Change | NT$- | -9.18% |
Book Value vs Market Value Analysis
This analysis compares Dabomb Protein's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.68x to 1.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$24.26 | NT$16.55 | x |
| 2018-12-31 | NT$24.29 | NT$16.55 | x |
| 2019-12-31 | NT$23.78 | NT$16.55 | x |
| 2020-12-31 | NT$21.12 | NT$16.55 | x |
| 2021-12-31 | NT$20.76 | NT$16.55 | x |
| 2022-12-31 | NT$18.79 | NT$16.55 | x |
| 2023-12-31 | NT$17.91 | NT$16.55 | x |
| 2024-12-31 | NT$16.02 | NT$16.55 | x |
| 2025-12-31 | NT$13.75 | NT$16.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dabomb Protein utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.42%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.11x
- Recent ROE (-7.01%) is below the historical average (0.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 10.49% | 7.73% | 1.10x | 1.23x | NT$2.92 Million |
| 2016 | 11.02% | 9.40% | 0.89x | 1.32x | NT$6.33 Million |
| 2017 | 4.50% | 4.98% | 0.66x | 1.37x | NT$-34.25 Million |
| 2018 | 3.54% | 4.04% | 0.74x | 1.18x | NT$-45.91 Million |
| 2019 | 3.03% | 3.28% | 0.70x | 1.32x | NT$-48.65 Million |
| 2020 | 1.03% | 1.19% | 0.57x | 1.51x | NT$-62.86 Million |
| 2021 | -9.26% | -13.27% | 0.35x | 1.98x | NT$-129.87 Million |
| 2022 | -6.14% | -10.30% | 0.34x | 1.76x | NT$-117.38 Million |
| 2023 | -5.95% | -14.83% | 0.27x | 1.46x | NT$-152.83 Million |
| 2024 | 1.07% | 3.44% | 0.26x | 1.21x | NT$-97.29 Million |
| 2025 | -7.01% | -22.42% | 0.28x | 1.11x | NT$-168.27 Million |
Industry Comparison
This section compares Dabomb Protein's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $26,262,476,200
- Average return on equity (ROE) among peers: 5.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dabomb Protein (6578) | NT$989.28 Million | 10.49% | 0.11x | $37.51 Million |
| Wei Chuan Foods Corp (1201) | $3.37 Billion | 0.00% | 2.77x | $198.50 Million |
| Ve Wong Corp (1203) | $5.15 Billion | 5.18% | 0.61x | $323.15 Million |
| Great Wall Enterprise Co Ltd (1210) | $35.47 Billion | 10.22% | 1.15x | $1.45 Billion |
| Charoen Pokphand Enterprise Taiwan Co Ltd (1215) | $2.36 Billion | 0.12% | 0.82x | $1.08 Billion |
| Uni-President Enterprises Corp (1216) | $195.21 Billion | 9.39% | 2.41x | $13.61 Billion |
| AGV Products Corp (1217) | $7.40 Billion | 2.72% | 0.87x | $154.09 Million |
| Taisun Enterprise Co Ltd (1218) | $3.86 Billion | 5.19% | 1.17x | $275.03 Million |
| Fwusow Industry Co Ltd (1219) | $4.43 Billion | 7.26% | 1.32x | $135.46 Million |
| Tai Roun Products Co Ltd (1220) | $1.69 Billion | 0.00% | 0.47x | $65.02 Million |
| Formosa Oilseed Processing Co Ltd (1225) | $3.68 Billion | 10.47% | 0.81x | $251.88 Million |
About Dabomb Protein
DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its n… Read more